Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease

NEW YORK, March 21, 2019 /PRNewswire/ -- Neurotrope Inc. NTRP, a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer's disease.

Neurotrope CEO, Dr. Charles Ryan, said in a statement, "We are deeply saddened to hear the news that Biogen and Eisai's efforts have fallen short. We, as a global society, are all in this fight together as we search for a cure for this devastating disease that is touching so many lives. Repeated attempts to treat or even slow the relentless progression of AD by targeting amyloid plaque in patient's brains continues to lead to disappointing outcomes. The promising data from our previous exploratory Phase 2 trial showed greater than baseline improvements in Severe Impairment Battery (SIB) scores for patients in the 20 µg Bryostatin-1 dose group, suggesting the potential to translate Bryostatin's neurorestorative properties in the clinic. Neurotrope will be releasing results of our confirmatory Phase 2 clinical trial using our drug Bryostatin during the second half of 2019."

About Neurotrope

Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

In addition to the Company's Phase 2 trial of Bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of Bryostatin-1 as a potential treatment for rare diseases and brain injury, including Fragile X syndrome, multiple sclerosis, stroke, Niemann-Pick Type C disease, Rett syndrome, and traumatic brain injury. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.

Please visit www.neurotrope.com for further information.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for AD, dementia and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2018. The Company does not undertake to update these forward-looking statements.

Contact information:

Investors

Tom Caden

Vice President

CORE IR

516 222 2560

tomc@coreir.com

www.coreir.com

Media

Jules Abraham

CORE IR

917 885 7378

julesa@coreir.com



Cision View original content:http://www.prnewswire.com/news-releases/neurotrope-comments-on-biogens-discontinued-phase-3-trial-in-alzheimers-disease-300816457.html

SOURCE Neurotrope Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Small CapPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!